Sylentis
Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.
This article has been updated to correct details regarding SYL1001's development timeline.
Title: Inducible Small RNA Expression Constructs for Targeted Gene Silencing
Patent Number: 8,198,077
Filed: Jan. 15, 2004
Lead Inventor: Thomas Tuschl, Max Plank Institute
Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.
The company said the Spanish Agency for Medicines and Healthcare Products has cleared its lab to make pharmaceutical compounds for research.
Sep 9, 2010
Jul 8, 2010
Apr 29, 2010
Nov 12, 2009
Aug 20, 2009
Feb 19, 2009